Summary
HCA Healthcare, Inc. reported solid financial results for the first quarter of 2023, demonstrating revenue growth and improved profitability. Total revenues increased by 4.3% to $15.591 billion compared to the prior year, driven by a significant increase in equivalent admissions. Net income attributable to HCA Healthcare, Inc. also saw a healthy rise of 7.1% to $1.363 billion, resulting in earnings per diluted share of $4.85. The company's operational performance was characterized by a notable increase in patient volumes, with equivalent admissions up 6.7% and same-facility admissions rising by 4.4%. This growth was supported by a higher volume of surgeries and emergency department visits. While revenue per equivalent admission experienced a slight decline, this was largely attributed to the comparison with a prior year period that included higher COVID-19 volumes and reimbursement. From a financial health perspective, cash flow from operations significantly improved, increasing by $458 million to $1.803 billion, driven by both increased net income and favorable changes in working capital. Despite a robust increase in capital expenditures to support facility improvements and expansion, the company maintained its liquidity. HCA Healthcare also continued its commitment to shareholder returns through share repurchases and dividend declarations.
Financial Highlights
46 data points| Revenue | $15.59B |
| Operating Expenses | $13.67B |
| Interest Expense | $479.00M |
| Net Income | $1.36B |
| EPS (Basic) | $4.92 |
| EPS (Diluted) | $4.85 |
| Shares Outstanding (Basic) | 276.91M |
| Shares Outstanding (Diluted) | 280.96M |
Key Highlights
- 1Total revenues for Q1 2023 increased by 4.3% to $15.591 billion year-over-year.
- 2Net income attributable to HCA Healthcare, Inc. grew by 7.1% to $1.363 billion, with diluted EPS of $4.85.
- 3Equivalent admissions increased by 6.7% in Q1 2023 compared to Q1 2022, indicating strong patient volume growth.
- 4Cash flow from operating activities saw a substantial increase of $458 million, reaching $1.803 billion in Q1 2023.
- 5Capital expenditures were elevated at $1.197 billion (excluding acquisitions) for Q1 2023, with full-year planned expenditures of approximately $4.6 billion.
- 6The company repurchased $846 million of its common stock in Q1 2023.
- 7Total uncompensated care costs were $831 million in Q1 2023, an increase from $792 million in Q1 2022.